Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 18.35 USD 7.06% Market Closed
Market Cap: 616.6m USD
Have any thoughts about
Grail Inc?
Write Note

Grail Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Grail Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
EPS (Diluted)
-$55
CAGR 3-Years
-213%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$2
CAGR 3-Years
-12%
CAGR 5-Years
6%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$0
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$7
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$40
CAGR 3-Years
-13%
CAGR 5-Years
16%
CAGR 10-Years
30%
No Stocks Found

Grail Inc
Glance View

Market Cap
609.3m USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
22.17 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Grail Inc's EPS (Diluted)?
EPS (Diluted)
-55.2 USD

Based on the financial report for Dec 31, 2023, Grail Inc's EPS (Diluted) amounts to -55.2 USD.

What is Grail Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-213%

Over the last year, the EPS (Diluted) growth was 73%. The average annual EPS (Diluted) growth rates for Grail Inc have been -213% over the past three years .

Back to Top